ZA200301162B - Gem-substituted alpha V beta 3 integrin antagonists. - Google Patents

Gem-substituted alpha V beta 3 integrin antagonists.

Info

Publication number
ZA200301162B
ZA200301162B ZA200301162A ZA200301162A ZA200301162B ZA 200301162 B ZA200301162 B ZA 200301162B ZA 200301162 A ZA200301162 A ZA 200301162A ZA 200301162 A ZA200301162 A ZA 200301162A ZA 200301162 B ZA200301162 B ZA 200301162B
Authority
ZA
South Africa
Prior art keywords
gem
beta
integrin antagonists
substituted alpha
alpha
Prior art date
Application number
ZA200301162A
Other languages
English (en)
Inventor
Ish Kumar Khanna
Yi Yu
Hwang Fun-Lu
Nizal S Chandrakumar
Renee M Huff
Mark A Russell
Mark L Boys
Lori A Schretzman
Barbara B Chen
Bipinchandra N Desai
Srinivasan R Nagarajan
Alan F Gasiecki
Thomas D Penning
Thomas Rogers
John Adam Wendt
Albert Khilevich
Yaping Wang
Balekudru Devadas
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of ZA200301162B publication Critical patent/ZA200301162B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
ZA200301162A 2000-08-30 2003-02-12 Gem-substituted alpha V beta 3 integrin antagonists. ZA200301162B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22918600P 2000-08-30 2000-08-30

Publications (1)

Publication Number Publication Date
ZA200301162B true ZA200301162B (en) 2004-05-12

Family

ID=22860154

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200301162A ZA200301162B (en) 2000-08-30 2003-02-12 Gem-substituted alpha V beta 3 integrin antagonists.

Country Status (16)

Country Link
EP (1) EP1313705A1 (xx)
JP (1) JP2004510708A (xx)
KR (1) KR20030027106A (xx)
CN (1) CN1471512A (xx)
AU (1) AU2001288515A1 (xx)
BR (1) BR0113671A (xx)
CA (1) CA2419699A1 (xx)
CZ (1) CZ2003459A3 (xx)
EA (1) EA200300226A1 (xx)
IL (1) IL154496A0 (xx)
MX (1) MXPA03001759A (xx)
NO (1) NO20030925L (xx)
NZ (1) NZ524159A (xx)
PL (1) PL365729A1 (xx)
WO (1) WO2002018340A1 (xx)
ZA (1) ZA200301162B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054663A1 (en) * 2003-08-13 2005-03-10 Bennett Christina N. GSK-3 inhibitors
US20080064716A1 (en) * 2004-10-14 2008-03-13 Pharmacia Biphenyl Integrin Antagonists
CN101880270B (zh) * 2009-05-07 2012-10-03 上海华升生物科技有限公司 一种制备1,1-环丙烷二甲醇环亚硫酸酯的方法
EP4249471A3 (en) 2013-09-24 2023-10-18 FUJIFILM Corporation Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof
KR20220102669A (ko) * 2019-10-16 2022-07-20 모픽 테라퓨틱, 인코포레이티드 인간 인테그린 α4β7의 억제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
EP0906103A1 (en) * 1995-12-29 1999-04-07 Smithkline Beecham Corporation Vitronectin receptor antagonists
US5919792A (en) * 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
US6239138B1 (en) * 1997-07-25 2001-05-29 Smithkline Beecham Corporation Vitronectin receptor antagonist
EP1017387A4 (en) * 1997-09-24 2004-08-18 Smithkline Beecham Corp VITRONEECT RECEPTOR ANTAGONIST

Also Published As

Publication number Publication date
EA200300226A1 (ru) 2003-10-30
NZ524159A (en) 2004-08-27
PL365729A1 (en) 2005-01-10
BR0113671A (pt) 2004-01-06
EP1313705A1 (en) 2003-05-28
KR20030027106A (ko) 2003-04-03
JP2004510708A (ja) 2004-04-08
WO2002018340A1 (en) 2002-03-07
AU2001288515A1 (en) 2002-03-13
CZ2003459A3 (cs) 2003-09-17
CA2419699A1 (en) 2002-03-07
MXPA03001759A (es) 2004-11-01
NO20030925D0 (no) 2003-02-27
IL154496A0 (en) 2003-09-17
NO20030925L (no) 2003-04-24
CN1471512A (zh) 2004-01-28

Similar Documents

Publication Publication Date Title
DE60136818D1 (en) 17.beta.-carbothioat 17.alpha.-arylkarbonyloxyloxy androstanderivate als anti-phlogistische medikamente
HRP20020375A2 (en) Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof
MXPA02001088A (es) 2-pirazolin-5-onas..
MXPA02007289A (es) Agonistas y antagonistas novedosos de receptores de melanocortina.
AU3213799A (en) Integrin antagonists
ZA200201269B (en) Toothbrush.
EP1254116A4 (en) ALPHA V INTEGRIN RECEPTOR ANTAGONISTS
EP1105389A4 (en) INTEGRIN RECEPTOR ANTAGONISTS
MXPA03003322A (es) Subunidad de alfa de la beta2 integrina humana novedosa.
IL156939A0 (en) Urea derivatives as integrin alpha 4 antagonists
MXPA03005743A (es) Antagonistas muscarinicos.
EP1252162A4 (en) ALPHA V INTEGRIN RECEPTOR ANTAGONISTS
MXPA03004932A (es) 2-anilino-bencimidazoles sustituidos y su uso como inhibidores de nhe.
AU2001234741A1 (en) Integrin antagonists
AU2001290772A1 (en) Alpha v integrin receptor antagonists
AU9259801A (en) Alpha v integrin receptor antagonists
HK1042037A1 (en) Vitronectin receptor antagonist.
ZA200202530B (en) Fabric care composition.
ZA200301162B (en) Gem-substituted alpha V beta 3 integrin antagonists.
HK1049110A1 (en) Vitronectin receptor antagonists.
ZA971184B (en) Endothelin antagonists.
AU9088401A (en) Alpha v integrin receptor antagonists
GB2337048B (en) 2,1,3-Benzothiadiazole containing endothelin antagonists
ZA991884B (en) Vitronectin receptor antagonists.
GB0020760D0 (en) W.I.Type 1